Mateusz Kaczmarek

Mateusz Kaczmarek

Mateusz Kaczmarek is a financial and technology journalist at TS2.tech, covering stocks, artificial intelligence, semiconductors and global market developments. A graduate of the Poznań University of Economics and Business, he previously worked in financial analysis before moving into business journalism. His reporting focuses on technology companies, market trends and the forces shaping global investment markets. Follow Mateusz Kaczmarek on Google News.

Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics Inc. is back in the spotlight today after investors digested last week’s surprise acquisition agreement with XenoTherapeutics, Inc., a Massachusetts-based non‑profit biotech. The stock is trading sharply higher and unusually active as the market prices in a mostly cash takeover and a complex contingent value right structure that could unlock additional upside over the coming decade. Repare Therapeutics+1
GameStop Stock (GME) on November 17, 2025: Retail Buzz, ‘Trade Anything Day’ Hype and New Short‑Squeeze Speculation

GameStop Stock (GME) on November 17, 2025: Retail Buzz, ‘Trade Anything Day’ Hype and New Short‑Squeeze Speculation

On Monday, November 17, 2025, GameStop is back at the center of the market conversation as its share price hovers just above $20 while retail traders debate new lows, short‑squeeze odds, and the company’s latest viral promotion, “Trade Anything Day.” At the same time, analysts are re‑running their models on GameStop’s valuation after a profitable streak, Bitcoin‑linked treasury moves and a massive convertible note sale earlier this year. markets.businessinsider.com+2Simply Wall St+2
17 November 2025
Ford Stock Soars in 2025 as Wall Street Backs EV Reset, Hybrids and an Amazon-Powered Digital Pivot

Ford Stock Soars in 2025 as Wall Street Backs EV Reset, Hybrids and an Amazon-Powered Digital Pivot

Ford Motor Company has quietly become one of 2025’s unlikeliest comeback stories. After years of a sluggish share price, the stock is up roughly one‑third this year, outpacing the broader market, even as its electric‑vehicle unit bleeds billions of dollars. Fresh reports and analyst notes published today, 17 November 2025, show why Wall Street is suddenly “in love” with Ford again — and why the story is more complicated than a simple turnaround. 24/7 Wall St.+1
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer’s acquisition of Metsera, Inc. is now effectively complete, Metsera’s stock has been delisted, major index providers are removing the name, and antitrust scholars are using the failed Novo Nordisk bid as a case study in “attempted monopolization.” Here’s a full rundown of what matters today, 17 November 2025, for anyone following Metsera, MTSR, or the obesity‑drug arms race.
Ondas Holdings (ONDS) Lands $8.2M Airport Drone Defense Deal and Closes $225M Sentrycs Acquisition on November 17, 2025

Ondas Holdings (ONDS) Lands $8.2M Airport Drone Defense Deal and Closes $225M Sentrycs Acquisition on November 17, 2025

Ondas Holdings Inc., a provider of autonomous drone systems and private wireless networks, packed several major announcements into Monday, November 17, 2025 – including a new multimillion‑dollar European airport contract, the closing of a $225 million acquisition, and fresh bullish analyst signals. Stock Titan
1 54 55 56 57 58 173
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

AerCap

NYSE: AER 95 / 100
#2 BUY

Uber

NYSE: UBER 93 / 100
#3 BUY ON WEAKNESS

Taiwan Semiconductor

NYSE: TSM 91 / 100
#4 TACTICAL BUY

dLocal

NASDAQ: DLO 88 / 100
#5 BUY THE RESET

Tapestry

NYSE: TPR 86 / 100
View full portfolio
Editorial model selection. Not personalised advice.